Ultragenyx (RARE) Posts New Data From Bone Disease Study

Zacks06-12

Ultragenyx Pharmaceutical Inc. RARE, along with partner Mereo BioPharma (MREO), announced new positive 14-month data from the phase II portion of the phase II/III Orbit study evaluating setrusumab (...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2443156268?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","is_english":true,"pubTime":"2024-06-12 22:46","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2443156268","market":"us","top_or_hot":-1,"title":"Ultragenyx (RARE) Posts New Data From Bone Disease Study","media":"Zacks","content":"<div>\n<p>Ultragenyx Pharmaceutical Inc. RARE, along with partner Mereo BioPharma (MREO), announced new positive 14-month data from the phase II portion of the phase II/III Orbit study evaluating setrusumab (...</p>\n\n<a href=\"https://finance.yahoo.com/news/ultragenyx-rare-posts-data-bone-144600431.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ultragenyx (RARE) Posts New Data From Bone Disease Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUltragenyx (RARE) Posts New Data From Bone Disease Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-12 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ultragenyx-rare-posts-data-bone-144600431.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ultragenyx Pharmaceutical Inc. RARE, along with partner Mereo BioPharma (MREO), announced new positive 14-month data from the phase II portion of the phase II/III Orbit study evaluating setrusumab (...</p>\n\n<a href=\"https://finance.yahoo.com/news/ultragenyx-rare-posts-data-bone-144600431.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NERV","symbol_name":"Minerva Neurosciences","start_time":0,"source_url":"https://finance.yahoo.com/news/ultragenyx-rare-posts-data-bone-144600431.html","article_id":"2443156268","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2443156268","pubTimestamp":1718203560,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Ultragenyx Pharmaceutical Inc. RARE, along with partner Mereo BioPharma , announced new positive 14-month data from the phase II portion of the phase II/III Orbit study evaluating setrusumab  in patients with osteogenesis imperfecta .The data showed that the large reduction in fracture rates previously reported in patients treated for a minimum of six months was sustained in patients treated for at least 14 months.OI is a group of genetic disorders that impact bone metabolism. It is characterized by increased bone fragility and a high risk of fractures. Currently, there are no approved treatments for this debilitating condition, representing a highly unmet medical need.As of the data cut-off date of May 24, 2024, the new data showed that treatment with setrusumab resulted ina large, sustained 67% reduction in annualized fracture rate and persistent median annualized fracture rate of 0.00.Treatment with setrusumab also resulted in clinically meaningful continued improvement in lumbar sp","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NERV":"Minerva Neurosciences","MRNS":"Marinus Pharmaceuticals","BK4139":"生物科技","BK4505":"高瓴资本持仓","RARE":"Ultragenyx Pharmaceutical Inc","BK4007":"制药","ACRV":"Acrivon Therapeutics, Inc.","BK4126":"金属与玻璃容器","MREO":"Mereo Biopharma Group Plc","OI":"欧文斯伊利诺玻璃"},"translate_title":"Ultragenyx（罕见）发布骨病研究的新数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACRV":1,"MREO":1,"MRNS":1,"NERV":1,"OI":1,"RARE":1},"content_text":"Ultragenyx Pharmaceutical Inc. RARE, along with partner Mereo BioPharma (MREO), announced new positive 14-month data from the phase II portion of the phase II/III Orbit study evaluating setrusumab (UX143) in patients with osteogenesis imperfecta (OI).\nThe data showed that the large reduction in fracture rates previously reported in patients treated for a minimum of six months was sustained in patients treated for at least 14 months.\nOI is a group of genetic disorders that impact bone metabolism. It is characterized by increased bone fragility and a high risk of fractures. Currently, there are no approved treatments for this debilitating condition, representing a highly unmet medical need.\nAs of the data cut-off date of May 24, 2024, the new data showed that treatment with setrusumab resulted in a large, sustained 67% reduction in annualized fracture rate and persistent median annualized fracture rate of 0.00.\nTreatment with setrusumab also resulted in clinically meaningful continued improvement in lumbar spine bone mineral density (BMD) with a mean increase from baseline of 22% at the 12-month timepoint.\nPreviously, the company reported that treatment with setrusumab for at least six months reduced the annualized fracture rate by 67% in patients with OI.\nPer the company, the new data underlines the potential of setrusumab in reducing the incidence of fractures and improving BMD in patients with OI.\nNo treatment-related serious adverse effects were seen as of the data cut-off date.\nShares of Ultragenyx have plunged 13.4% so far this year compared with the industry’s decline of 5.5%.\nImage Source: Zacks Investment Research\nSetrusumab, a fully human monoclonal antibody, is an inhibitor of the sclerostin protein, which is responsible for hampering the maturation and activity of bone-forming cells.\nWe would like to remind investors that Ultragenyx entered into a licensing and collaboration agreement with Mereo in December 2020 to co-develop setrusumab. Per the terms of the agreement, Ultragenyx leads the global development of setrusumab in both pediatric and adult patients with OI.\nAs part of this deal, Mereo received an upfront payment of $50 million from RARE, while the latter is eligible for certain regulatory and sales-based milestone payments.\nMeanwhile, enrollment in the pivotal phase III portion of the phase II/III Orbit study has been completed. Patients in this portion of the study will be divided into two cohorts in a ratio of 2:1, receiving either a 20 mg/kg dose of setrusumab or a placebo. The primary efficacy endpoint of the study is the annualized clinical fracture rate. Per Ultragenyx, all patients will transition to an extension period and receive open-label setrusumab after completing the primary analysis in the phase III portion of the study.\nApart from the Orbit study, the phase III Cosmic study is also evaluating the effect of setrusumab compared with intravenous bisphosphonate therapy on the annualized total fracture rate in patients aged 2 to <7 years. Enrollment in this study has also been completed.\nZacks Rank & Stocks to Consider\nUltragenyx currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the healthcare sector are Acrivon Therapeutics, Inc. ACRV, Marinus Pharmaceuticals, Inc. MRNS and Minerva Neurosciences, Inc. NERV, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nIn the past 60 days, estimates for Acrivon Therapeutics’ 2024 loss per share have narrowed from $3.42 to $2.47. Loss per share estimates for 2025 have narrowed from $3.36 to $2.55. Year to date, shares of ACRV have surged 50.4%.\nACRV’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining one occasion, the average surprise being 3.56%.\nIn the past 60 days, estimates for Marinus Pharmaceuticals’ 2024 loss per share have narrowed from $2.43 to $1.87, while loss per share estimates for 2025 have narrowed from $1.97 to 90 cents. Year to date, shares of MRNS have plunged 85.7%.\nMRNS’s earnings beat estimates in two of the trailing four quarters, met the same once and missed the same once, the average surprise being 3.27%.\nIn the past 60 days, estimates for Minerva Neurosciences’ 2024 loss per share have narrowed from $3.57 to $1.89. Loss per share estimates for 2025 have narrowed from $4.54 to $3.60. Year to date, shares of NERV have declined 47.1%.\nNERV’s earnings beat estimates in one of the trailing four quarters while missing the same on the remaining three occasions, the average negative surprise being 54.43%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nUltragenyx Pharmaceutical Inc. (RARE) : Free Stock Analysis Report\nMinerva Neurosciences, Inc (NERV) : Free Stock Analysis Report\nMarinus Pharmaceuticals, Inc. (MRNS) : Free Stock Analysis Report\nAcrivon Therapeutics, Inc. (ACRV) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2443156268"}